Citadel Advisors’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Citadel Advisors’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,300	Closed	-$410K	–	15807
2024 Q3	$410K	Buy	12,300 +3,800	+45%	+$131K	﹤0.01%	8687
2024 Q2	$230K	Buy	8,500 +6,100	+254%	+$120K	﹤0.01%	9638
2024 Q1	$51.8K	Buy	+2,400	New	+$52.3K	﹤0.01%	12144

Citadel Advisors's LBPH Position: Q2 2024 in Review

Citadel Advisors sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q2 2024, closing a stake of 147,323 shares — an estimated $2.91M sold.

Citadel Advisors first reported a position in LBPH in Q1 2021 and held it in 2 quarters. The position peaked at $3.18M in Q1 2024. 100 funds tracked by Wall St. Rank hold LBPH as of Q2 2024.

Citadel Advisors reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 147,323 Longboard Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $2.91M.
Citadel Advisors first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
Citadel Advisors's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $3.18M in Q1 2024.
100 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.